Cidara Therapeutics, Inc. (CDTX) has an overall financial health rating of C with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2026-01-06.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-01-06 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-01-05 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-01-02 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-12-31 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-12-30 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-12-29 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-12-26 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-12-24 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-12-23 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-12-22 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-12-19 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-12-18 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
